Clinical Trial · NCT06543108

Preliminary Study on the Diagnostic Value Comparison of 18F-FAPI-04 PET/CT and PET/MR in Gastric Cancer

Overview

This project aims to comprehensively analyze the diagnostic efficacy of SUVmax, SUVean, TLG, MTV, etc. in gastric cancer through 18F-FAPI-04 PET/CT imaging combined with serum tumor markers and other methods, and construct a molecular imaging diagnostic model for gastric cancer; Next, analyze the diagnostic efficacy of 18F-FAPI-04 PET/CT and PET/MR multimodal imaging in evaluating SUVmax, PET/CT-PCI, and PET/MR-PCI for gastric cancer peritoneal metastasis, and construct a molecular imaging diagnostic model for gastric cancer peritoneal metastasis; Exploring the clinical value of 18F-FAPI-04 PET/CT and PET/MR imaging in the diagnosis and staging of gastric cancer.

Sponsor

Hunan Cancer Hospital

Contacts

Hui Ye (CONTACT)

yuxin75831@163.com

86-13755117105

ClinicalTrials.gov

NCT06543108

Drug / Compound

FAPI-04

Isotope(s):

Target(s):

Ligand Class: Small Molecules

Chelator: DOTA

Eligibility

Inclusion

Receive FAPI PET/CT and FDG PET/CT imaging within one week;
Perform serum tumor marker testing one week before and after scanning
Diagnosed as a patient with gastric cancer;

Exclusion

Patients with unorganized pathology or incomplete clinical data
Patients with contraindications for PET-CT examination, poor physical condition, and inability to tolerate the examination;
History of other malignant tumors;
Patients with severe infections, severe underlying diseases such as heart, kidney, and liver;